Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
Key Highlights
- ➤MHRA grants REDEMPLO marketing authorisation for adult FCS patients in the United Kingdom
- ➤NICE recommends NHS England and Wales funding for genetically confirmed adult FCS
- ➤PALISADE study shows plozasiran significantly reduced median fasting triglycerides at Month 10
- ➤REDEMPLO targets patients inadequately controlled by diet and conventional triglyceride-lowering therapies
Expert Statements
Kausik Ray, Professor of Public Health at Imperial College, London and Immediate Past President of the European Atherosclerosis Society
“People living with FCS face a life-long risk of recurrent and potentially fatal acute pancreatitis that might remain undiagnosed for years, and physicians now have an important new option to treat this debilitating disease.”
Kausik Ray, Professor of Public Health at Imperial College, London and Immediate Past President of the European Atherosclerosis Society
“Results from the PALISADE study demonstrate that plozasiran significantly reduced median fasting triglyceride levels at the 25 mg recommended dose (p <0.0001 vs placebo) at month 10.”
Kausik Ray, Professor of Public Health at Imperial College, London and Immediate Past President of the European Atherosclerosis Society
“By remaining aware of the combination of symptoms that suggest FCS, physicians can move to genetic testing earlier to confirm their diagnosis.”
Jill Prawer, Chair of Action FCS
“We warmly welcome today’s decision from NICE.”
Jill Prawer, Chair of Action FCS
“Due to the need for an extremely fat-restricted diet, living with FCS affects every area of life, and every meal eaten.”
Jill Prawer, Chair of Action FCS
“Alongside this can come the worry of a painful and debilitating attack of pancreatitis that can lead to time in hospital – time away from family, education and work.”
Jill Prawer, Chair of Action FCS
“The availability of this new treatment option on the NHS, alongside the diet, brings real hope to people living with FCS and those who care for them.”
Graham Skarnvad, General Manager and Head of Europe at Arrowhead Pharmaceuticals
“We are thrilled to bring REDEMPLO as a new treatment option, approved and reimbursed on the NHS in England for people living with FCS.”
Graham Skarnvad, General Manager and Head of Europe at Arrowhead Pharmaceuticals
“Supporting the FCS community in the UK is an important focus for us as we work to make plozasiran available for people living with FCS in several European countries over the coming months.”
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO(®) (Plozasiran) as a New Treatment Option to Reduce Triglycerides
* The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation for REDEMPLO(®) (plozasiran) as an adjunct to diet to reduce triglyceride levels in adult patients with Familial Chylomicronaemia Syndrome (FCS) diagnosed via genetic testing or clinical criteria(1)
Get started
Create a free account to read the full story.